News Summaries

How Cutting‑Edge Tech From VR to 6G Is Shaping Our Future

A wave of breakthroughs is turning science‑fiction ideas into everyday reality. Researchers have shown that ordinary Wi‑Fi signals—those invisible waves that keep us online—could double as stealthy surveillance tools, identifying people without cameras or even a smartphone. At the same time, engineers are pushing the limits of tiny electronics. A new 0.42‑nanometer transistor design promises to go beyond silicon, while atom‑thin semiconductors could make chips smaller and more efficient, despite stubborn material‑boundary challenges. Energy‑hungry data centers may soon get a boost from a novel fuel‑cell breakthrough, and microscopic, light‑driven robots are already being tested as tiny cleaners that can swim through liquids, gather bacteria, and deposit them where needed—opening fresh possibilities for medical and environmental work. In the optics world, Caltech scientists have crafted ultra‑low‑loss pathways on silicon chips that rival fiber‑optic performance, paving the way for stronger lasers and faster data links. Even DNA is getting a tech makeover, being turned into a memory device that slashes power use by a factor of 100. Meanwhile, a "rainbow on a chip"—a miniature light source that emits a stable spectrum—could supercharge the next generation of 6G networks, delivering unprecedented speed and capacity. Finally, new research suggests that screen time at ages one and six may have deeper impacts on child development than parents realize, underscoring the need for mindful tech use from the earliest years.

Inside the 2026 Issue of the Chinese Journal of New Drugs: Breakthroughs from Pain Relief to AI‑Driven Antibiotics

The latest issue of the Chinese Journal of New Drugs showcases a vibrant mix of cutting‑edge research aimed at improving patient care. One study explores highly selective κ‑opioid receptor agonists that promise powerful pain relief with fewer side effects. Another highlights how artificial intelligence and big‑data analytics are reshaping the discovery of anti‑infective medicines, speeding up the hunt for new antibiotics. In oncology, researchers introduce Tarlatamab, a novel bispecific T‑cell engager that targets DLL3/CD3 to attack small‑cell lung cancer more precisely. A separate team reports a rapid nucleic‑acid detection system for three genotypes of human parvovirus B19, offering faster diagnosis. Traditional Chinese Medicine (TCM) gets its turn, with investigations into the fever‑reducing action of Binaxifu granules and a deep dive into the synergistic ratios of active compounds in TCM formulas. Pharmaceutical formulation advances are also featured, including a lipid‑nanoparticle delivery platform for the prostate‑cancer drug Abiraterone acetate. Policy analysts compare China‑EU regulatory approaches under ICH Q12 for post‑approval drug changes, while another paper examines how “three‑chain” integration boosts the productivity of leading TCM enterprises. Finally, the issue reviews patent opposition trends for TCM, advances molecular imaging probes targeting tumor CLDN18.2, and discusses novel drug‑formulation strategies that blend modern science with traditional wisdom. All these studies together paint a dynamic picture of innovation at the crossroads of chemistry, biology, technology, and policy.

China’s Cutting‑Edge Drug Discoveries: AI‑Powered Antivirals, New Cancer Immunotherapies, and Modern TCM Breakthroughs

The latest issue of the China Journal of New Drugs showcases a vibrant mix of pioneering research that could reshape modern medicine. Scientists report promising selective κ‑opioid receptor agonists that may deliver powerful pain relief without the side‑effects of traditional opioids. In parallel, a team harnesses artificial intelligence and big‑data analytics to accelerate the discovery of anti‑infective agents, opening a fast‑track to new antibiotics. A standout breakthrough is the bispecific T‑cell engager talquetamab, designed to target DLL3/CD3 and show potent activity against small‑cell lung cancer. Diagnostic advances include a nucleic‑acid test capable of detecting three genotypes of human parvovirus B19, improving early disease identification. Traditional Chinese Medicine (TCM) also gets a modern makeover: researchers unravel the fever‑reducing mechanism of Binaxi granules, develop a lipid‑nanoparticle formulation of the prostate‑cancer drug abiraterone acetate, and explore synergistic component ratios that boost efficacy. Policy analysts compare Sino‑European regulatory frameworks under ICH Q12, while case studies of TCM patent oppositions reveal emerging legal trends. Finally, innovative molecular imaging probes targeting tumor marker CLDN18.2 promise sharper cancer diagnostics. Together, these studies illustrate China’s dynamic push toward smarter, safer, and more effective therapeutics across the drug development spectrum.